olivLaw · European equity research
Clinica Baviera SA CBAV.MC
Spain · BME Madrid · ISIN ES0119037010 · Vertical: Listed companies from Spain
At the close of 05 Nov 2026, Clinica Baviera SA (CBAV.MC) stock was 52.80 EUR (+0.38% on the day), with dividend yield 2.97%, beta 0.26, 52-week range 40.30–61.40 EUR.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 36.4
- weak (30–45)
- Bollinger (20, 2)
- 52.42 – 55.64
- in the lower half of the band · %B 0.12 · band width 6.0%
- SMA 50 / 200
- 55.98 / 54.89
- mixed trend
- MACD (12, 26, 9)
- -0.83 / -0.84
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −3.6% | −0.6% | −3.0 pp | — |
| 3 months | −13.2% | −4.2% | −9.0 pp | — |
| 6 months | −6.7% | +4.3% | −11.0 pp | — |
| Year to date | +6.2% | +7.5% | −1.3 pp | — |
| 1 year | +28.2% | +9.9% | +18.2 pp | +3.2% |
| 3 years | +162.7% | +49.8% | +112.8 pp | +26.0% |
| 5 years | +179.4% | +42.8% | +136.5 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
EPS unavailable in the issuer's structured filings (e.g. a partnership reports per unit, not per share).
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 224.9 m | 262.6 m | 301.8 m |
| Revenue YoY | unavailable | +16.8% | +14.9% |
| Net income | 36.0 m | 40.2 m | 42.1 m |
| Net income YoY | unavailable | +11.8% | +4.6% |
| Diluted EPS | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | 16.0% | 15.3% | 13.9% |
| Free cash flow | 35.1 m | 36.0 m | 46.8 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 5.6 m EUR
- Financial debt
- unavailable EUR
- Net debt
- unavailable EUR
- Equity
- 111.0 m EUR
- Total assets
- 247.5 m EUR
- Debt / equity
- unavailable
- Current ratio
- 0.97x
- ROE
- 40.2%
- ROA
- 18.3%
- FCF margin
- 15.5%
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 224.9 m | 262.6 m | 301.8 m | esef· 20 Oct 2026verified |
| Operating income | 50.0 m | 55.7 m | 60.5 m | esef· 20 Oct 2026verified |
| Depreciation & amortisation | 17.0 m | 20.9 m | 23.9 m | esef· 20 Oct 2026verified |
| EBITDA | 67.0 m ≈ | 76.6 m ≈ | 84.4 m ≈ | esef· 20 Oct 2026derived |
| Interest expense | 571.7 k | 1.2 m | 2.3 m | esef· 20 Oct 2026verified |
| Pre-tax income | 49.7 m | 56.0 m | 60.1 m | esef· 20 Oct 2026verified |
| Income tax | 12.9 m | 14.9 m | 17.2 m | esef· 20 Oct 2026verified |
| Net income | 36.0 m | 40.2 m | 42.1 m | esef· 20 Oct 2026verified |
| Dividend per share | — | 1.57 | 1.57 | esef· 20 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 8.3 m | 10.1 m | 5.6 m | esef· 20 Oct 2026verified |
| Receivables | 3.0 m | 4.2 m | 4.7 m | esef· 20 Oct 2026verified |
| Inventories | 2.5 m | 3.3 m | 3.3 m | esef· 20 Oct 2026verified |
| Current assets | 57.7 m | 47.7 m | 59.3 m | esef· 20 Oct 2026verified |
| Property, plant & equipment, net | 99.1 m | 122.7 m | 142.5 m | esef· 20 Oct 2026verified |
| Goodwill | 14.6 m | 29.0 m | 29.0 m | esef· 20 Oct 2026verified |
| Intangibles (excl. goodwill) | 2.7 m | 8.7 m | 11.1 m | esef· 20 Oct 2026verified |
| Total assets | 178.6 m | 212.4 m | 247.5 m | esef· 20 Oct 2026verified |
| Current liabilities | 45.3 m | 50.4 m | 61.5 m | esef· 20 Oct 2026verified |
| Equity | 92.3 m | 98.4 m | 111.0 m | esef· 20 Oct 2026verified |
Cash flow · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 57.8 m | 62.5 m | 76.8 m | esef· 20 Oct 2026verified |
| Capex | 22.7 m | 26.5 m | 30.0 m | esef· 20 Oct 2026verified |
| Free cash flow | 35.1 m ≈ | 36.0 m ≈ | 46.8 m ≈ | esef· 20 Oct 2026derived |
| Investing cash flow | -44.3 m | -20.9 m | -45.0 m | esef· 20 Oct 2026verified |
| Financing cash flow | -24.4 m | -39.7 m | -36.5 m | esef· 20 Oct 2026verified |
| Dividends paid | 13.6 m | 25.9 m | 26.4 m | esef· 20 Oct 2026verified |
| Share repurchases | 706.5 k | 10.2 m | 2.4 m | esef· 20 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 27.1% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 21.35 – 29.12 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · input data missing
- Dividend discount (DDM)21.35 – 29.12 (Mid 24.64)
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 27.1% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 13.9% | 84 (vs peers) | 23% |
| FCF conversion · Quality | 111.3% | 100 (on a fixed band) | 23% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 26.5x | 100 (on a fixed band) | 23% |
| Current ratio · Balance sheet | 1.0x | 14 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | 56.4% | 91 (on a fixed band) | 15% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet66/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality92/100 · 2/3 factors with a value
- Returns· partial91/100 · 1/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
CLINICA BAVIERA SA (CBAV.MC). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 301.8 m EUR in 2025; YoY growth 14.9%; net margin 13.9%; ROE 40.7%.
The estimated value range is 21.35–29.12 EUR per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 24.64 EUR, the price of 52.80 EUR leaves a potential of -53.3% (value / price − 1) and a margin of safety of -114.3% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 27.1% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 13.9%
- FCF conversion: 111.3%
- Interest coverage: 26.5x
- Payout ratio (FCF): 56.4%
What contradicts it
- Current ratio: 1.0x
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): ROIC, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions).
Versus the vertical median
Listed companies from Spain · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ELE.MCEndesa SA | 46.9 bn | 21.4 | 26.4% | 10.5% | +0.5% | +43% / +134% |
| AENA.MCAena S.m.e. SA | 42.6 bn | 19.9 | 24.2% | 34.0% | +8.9% | +21% / +79% |
| AMS.MCAmadeus It Group Sociedad Anonima | 26.2 bn | 19.8 | 26.9% | 20.5% | +6.1% | −6% / −5% |
| ACS.MCAcs Actividades De Construccion Y Servicios, S.A. | 21.9 bn | 23.0 | 19.9% | 1.9% | +19.7% | +7% / +134% |
| ANA.MCAcciona SA | 11.7 bn | 14.5 | 16.9% | 4.0% | +5.5% | +24% / +66% |
| FCC.MCFomento De Construcciones Y Contratas S.A. | 5.0 bn | 30.3 | 5.3% | 1.7% | +6.9% | −8% / −14% |
| FDR.MCFluidra S.A. | 3.8 bn | 21.3 | 10.9% | 7.8% | +4.1% | −17% / +4% |
| DIA.MCDistribuidora Internacional De Alimentacion SA | 2.7 bn | 20.6 | 165.6% | 2.2% | −2.7% | +51% / +380,733% |
| CMO.MCCementos Molins S.A. | 2.5 bn | 13.6 | 14.3% | 18.0% | −3.1% | +31% / unavailable |
| ENO.MCElecnor SA | 2.4 bn | 21.9 | 10.5% | 2.5% | +15.1% | −3% / +58% |
| ALM.MCAlmirall S.A. | 2.4 bn | 51.1 | 3.1% | 4.2% | +12.4% | −11% / +32% |
| FAE.MCFaes Farma SA | 1.5 bn | 19.3 | 10.8% | 13.0% | +23.7% | +3% / +57% |
| AEDAS.MCAedas Homes SA | 1.0 bn | 17.1 | 57.8% | 7.0% | −24.8% | +0% / +38% |
| EDR.MCEdreams Odigeo SA | 574.4 m | 11.5 | 21.0% | 7.8% | −0.4% | +40% / −24% |
| EAT.MCAmRest Holdings SE | 506.0 m | 31.4 | 4.3% | 0.6% | +0.1% | −34% / −61% |
| ADX.MCAudax Renovables S.A. | 468.5 m | 23.9 | 9.3% | 1.0% | −5.4% | −23% / −18% |
| ATRY.MCAtrys Health, S.A. | 200.4 m | — | -49.5% | -71.1% | +8.5% | −3% / −29% |
| ENER.MCEcoener, S.A. | 175.6 m | 32.2 | 4.2% | 6.4% | +3.6% | −34% / −6% |
| ADZ.MCAdolfo Dominguez SA | 62.9 m | 38.3 | 9.0% | 1.2% | +1.8% | +39% / +40% |
| DESA.MCDesarrollos Especiales De Sistemas De Anclaje S.A. | 44.8 m | 9.2 | 152.3% | 10.0% | +2.2% | +19% / unavailable |
| EZE.MCGrupo Ezentis SA | 29.0 m | — | — | -9.3% | +147.2% | −30% / −37% |
| CLEO.MCCompañia Levantina De Edificacion Y Obras Publicas SA | 17.3 m | 14.4 | 4.1% | 3.4% | +13.4% | unavailable / unavailable |
| AYC.MCAyco Grupo Inmobiliario, S.A. | 16.4 m | — | -33.8% | — | −100.0% | unavailable / unavailable |
| EBRO.MCEbro Foods, S.A. | 3.0 m | 0.0 | 10.0% | 7.7% | −4.0% | −0% / +19% |
| A3M.MCAtresmedia Corporacion De Medios De Comunicacion, S.A. | — | — | 7.9% | 6.9% | −2.7% | +13% / +60% |
1- and 3-year price returns: for CBAV.MC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202520 Oct 2026
- Annual report 202408 May 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.